Hypertrophic Cardiomyopathy in Pregnancy.

Hypertrophic cardiomyopathy (HCM) is the most common genetic cardiac condition and highly heterogeneous. Echocardiography and genetic and clinical screening have led to detection in women of childbearing age. Maternal and fetal outcomes among women with HCM are favorable. Genetic counseling is recommended. Prepregnancy clinical evaluation and risk assessment are paramount in ensuring optimal outcomes. Most women carry moderate risk of morbidity, have clinical evaluations and echocardiography each trimester, and deliver vaginally. Those who are symptomatic or have significant left ventricular outflow obstruction or recurrent arrhythmias prior to pregnancy are at higher risk and should be monitored at least monthly.

• Publication year

  2021

• Venue

  Cardiology Clinics

• Publication date

  2021-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ccl.2020.09.009PMID 33222809
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Novel Oral Anticoagulants for Primary Stroke Prevention in Hypertrophic Cardiomyopathy Patients With Atrial Fibrillation.

  2019cited by this paper
• Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology

  2019cited by this paper
• Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy

  2018cited by this paper
• Successful alcohol septal ablation in a pregnant patient with symptomatic hypertrophic obstructive cardiomyopathy.

  2018cited by this paper
• Clinical Course and Management of Hypertrophic Cardiomyopathy

  2018cited by this paper
• 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.

  2018cited by this paper
• Hypertrophic Cardiomyopathy With Left Ventricular Apical Aneurysm: Implications for Risk Stratification and Management.

  2017cited by this paper
• Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC)

  2017cited by this paper
• Safety With Echocardiographic Contrast Agents

  2017cited by this paper
• Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH

  2016cited by this paper
• How Hypertrophic Cardiomyopathy Became a Contemporary Treatable Genetic Disease With Low Mortality: Shaped by 50 Years of Clinical Research and Practice.

  2016cited by this paper
• Diltiazem treatment for pre-clinical hypertrophic cardiomyopathy sarcomere mutation carriers: a pilot randomized trial to modify disease expression.

  2015cited by this paper
• Association of cardiomyopathy with adverse cardiac events in pregnant women at the time of delivery.

  2015cited by this paper
• Prediction of thrombo‐embolic risk in patients with hypertrophic cardiomyopathy (HCM Risk‐CVA)

  2015cited by this paper
• 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC).

  2014cited by this paper
• Hypertrophic cardiomyopathy: present and future, with translation into contemporary cardiovascular medicine.

  2014cited by this paper
• Pregnancy in Women With Hypertrophic Cardiomyopathy

  2014cited by this paper
• Are we missing hypertrophic cardiomyopathy in pregnancy? Experience of a tertiary care hospital.

  2014cited by this paper
• [2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy].

  2014cited by this paper
• ACR guidance document on MR safe practices: 2013

  2013cited by this paper
• Left ventricular chamber dimensions and wall thickness by cardiovascular magnetic resonance: comparison with transthoracic echocardiography.

  2013cited by this paper
• B-type natriuretic peptide and survival in hypertrophic cardiomyopathy.

  2013cited by this paper
• Prognostic value of N-terminal pro-brain natriuretic Peptide in outpatients with hypertrophic cardiomyopathy.

  2013cited by this paper
• Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy.

  2012cited by this paper
• Brain Natriuretic Peptide in Term Pregnancy

  2012cited by this paper
• Pregnancy in women with hypertrophic cardiomyopathy

  2012cited by this paper
• Controversies in cardiovascular medicine Pharmacological treatment options for hypertrophic cardiomyopathy : high time for evidence

  2012cited by this paper
• Pharmacological treatment options for hypertrophic cardiomyopathy: high time for evidence.

  2012cited by this paper
• 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines

  2011cited by this paper
• Electrical cardioversion during pregnancy: safe or not?

  2011cited by this paper
• Characteristics and Clinical Significance of Late Gadolinium Enhancement by Contrast-Enhanced Magnetic Resonance Imaging in Patients With Hypertrophic Cardiomyopathy

  2010cited by this paper
• B-type natriuretic peptide in pregnant women with heart disease.

  2010cited by this paper
• The Many Faces of Hypertrophic Cardiomyopathy: From Developmental Biology to Clinical Practice

  2009cited by this paper
• Hypertrophic Cardiomyopathy: Preclinical and Early Phenotype

  2009cited by this paper
• Longitudinal Changes in the B‐Type Natriuretic Peptide Levels in Normal Pregnancy and Postpartum

  2009cited by this paper
• Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy.

  2008cited by this paper
• Clinical Profile and Significance of Delayed Enhancement in Hypertrophic Cardiomyopathy

  2008cited by this paper
• Outcome of pregnancy in women with congenital heart disease: a literature review.

  2007cited by this paper
• Hyperthrophic obstructive cardiomyopathy and pregnancy: University College London Hospital experience.

  2007cited by this paper
• Perioperative Management of Patients with Implantable Cardioverter Defibrillators

  2007cited by this paper
• Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction

  2006cited by this paper
• Glycogen storage diseases presenting as hypertrophic cardiomyopathy.

  2005cited by this paper
• Historical trends in reported survival rates in patients with hypertrophic cardiomyopathy

  2005cited by this paper
• Utility of Cardiac Magnetic Resonance Imaging in the Diagnosis of Hypertrophic Cardiomyopathy

  2005cited by this paper
• Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography

  2004cited by this paper
• Hypertrophic cardiomyopathy: an important global disease.

  2004cited by this paper
• Pregnancy in patients with heart disease: Experience with 1,000 cases

  2003cited by this paper
• Toward clinical risk assessment in hypertrophic cardiomyopathy with gadolinium cardiovascular magnetic resonance.

  2003cited by this paper
• Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy.

  2002cited by this paper
• Prevalence of hypertrophic cardiomyopathy in a general population of young adults. Echocardiographic analysis of 4111 subjects in the CARDIA Study. Coronary Artery Risk Development in (Young) Adults.

  1995cited by this paper
• The effect of disopyramide on uterine contractions during pregnancy.

  1990cited by this paper
• Low Molecular Weight Heparin (CY 216) Does Not Cross the Placenta During the Third Trimester of Pregnancy

  1987cited by this paper
• Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy study by direct fetal blood sampling under ultrasound.

  1984cited by this paper

• Role of multimodality cardiac imaging in the management of patients with hypertrophic cardiomyopathy in 2025. A Clinical Consensus Statement of the European Association of Cardiovascular Imaging (EACVI) of the ESC.

  2025cites this paper
• Society for Maternal‐Fetal Medicine Consult Series #73: Diagnosis and management of right and left heart failure during pregnancy and postpartum

  2025cites this paper
• Management of hypertrophic cardiomyopathy

  2024cites this paper
• Introducing and Implementing Genetic Assessment in Cardio-Obstetrics Clinical Practice: Clinical and Genetic Workup of Patients with Cardiomyopathy

  2023cites this paper
• Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy: JACC: Heart Failure State-of-the-Art Review.

  2023cites this paper
• Cardiovascular evaluation of pregnant women with hypertrophic cardiomyopathy

  2022cites this paper
• Pregnancy heart team: A lesion-specific approach.

  2022cites this paper
• Cardiovascular Imaging in Pregnancy: Valvulopathy, Hypertrophic Cardiomyopathy, and Aortopathy

  2022cites this paper
• Sex Differences in Hypertrophic Cardiomyopathy: Interaction With Genetics and Environment

  2021cites this paper